Jersey Shore NJ
Revolution Medicines and Amgen Partner on Phase 1b Study to Evaluate Combination of RMC-4630 and AMG 510
REDWOOD CITY, Calif., Nov. 4, 2019 /PRNewswire/ -- Revolution Medicines, Inc., a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive frontie…
